Jasper Therapeutics, Inc. (NASDAQ:JSPR) Short Interest Up 10.2% in November

Jasper Therapeutics, Inc. (NASDAQ:JSPR) saw a large growth in short interest in November. As of November 15th, there was short interest totalling 1,940,000 shares, a growth of 10.2% from the October 31st total of 1,760,000 shares. Approximately 17.2% of the company’s stock are short sold. Based on an average trading volume of 275,500 shares, the days-to-cover ratio is currently 7.0 days.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on JSPR. Cantor Fitzgerald restated an “overweight” rating on shares of Jasper Therapeutics in a report on Monday, September 9th. HC Wainwright reaffirmed a “buy” rating and set a $65.00 price target on shares of Jasper Therapeutics in a research report on Thursday, October 24th. JMP Securities reissued a “market outperform” rating and issued a $70.00 price objective on shares of Jasper Therapeutics in a report on Tuesday, October 15th. Royal Bank of Canada lowered their price target on Jasper Therapeutics from $70.00 to $68.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 14th. Finally, Evercore ISI reissued an “outperform” rating and issued a $65.00 price target on shares of Jasper Therapeutics in a report on Monday, August 26th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Jasper Therapeutics currently has a consensus rating of “Buy” and an average price target of $74.86.

Jasper Therapeutics Price Performance

Shares of NASDAQ JSPR opened at $23.62 on Wednesday. The stock has a market capitalization of $354.30 million, a PE ratio of -4.98 and a beta of 2.18. Jasper Therapeutics has a fifty-two week low of $4.00 and a fifty-two week high of $31.01. The business has a fifty day moving average price of $20.32 and a two-hundred day moving average price of $20.92.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of JSPR. BNP Paribas Financial Markets increased its holdings in Jasper Therapeutics by 208.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock valued at $47,000 after buying an additional 1,698 shares during the period. Wolff Wiese Magana LLC bought a new position in Jasper Therapeutics in the third quarter valued at approximately $59,000. MetLife Investment Management LLC raised its position in Jasper Therapeutics by 129.1% during the third quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock valued at $129,000 after purchasing an additional 3,873 shares in the last quarter. Virtu Financial LLC bought a new stake in Jasper Therapeutics during the first quarter worth $306,000. Finally, Rhumbline Advisers acquired a new stake in shares of Jasper Therapeutics in the 2nd quarter valued at $300,000. Institutional investors and hedge funds own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.